Ikena Oncology, Inc. (IKNA)

US — Healthcare Sector
Peers: EWTX  DSGN  XLO  ELYM  GLUE  HOWL  STOK  ANEB  CELC  MNOV  RZLT  AVTE  DBTX  FHTX  STTK  KYMR  NRIX 

Automate Your Wheel Strategy on IKNA

With Tiblio's Option Bot, you can configure your own wheel strategy including IKNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IKNA
  • Rev/Share 0.0
  • Book/Share 2.4504
  • PB 0.4856
  • Debt/Equity 0.0559
  • CurrentRatio 13.3059
  • ROIC -0.4048

 

  • MktCap 57427139.0
  • FreeCF/Share -0.7929
  • PFCF -1.5009
  • PE -1.3769
  • Debt/Assets 0.0505
  • DivYield 0
  • ROE -0.32

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Ikena Oncology, Inc. (IKNA)

  • IPO Date 2021-03-26
  • Website https://ikenaoncology.com
  • Industry Biotechnology
  • CEO Dr. Mark Manfredi Ph.D.
  • Employees 10

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.